Orphan designation: (4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-1-carboximidamide hydrochloride Treatment of systemic sclerosis, 12/01/2024 Positive

Orphan designation: (4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-1-carboximidamide hydrochloride Treatment of systemic sclerosis, 12/01/2024 Positive

Human medicines European public assessment report (EPAR): Ambrisentan Mylan, ambrisentan, Date of authorisation: 20/06/2019, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ambrisentan Mylan, ambrisentan, Date of authorisation: 20/06/2019, Revision: 5, Status: Authorised

EMA/FVE info session on restrictions of certain antimicrobials, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 15:00 (CEST) to 23 May 2024, 16:00 (CEST)

EMA/FVE info session on restrictions of certain antimicrobials, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 15:00 (CEST) to 23 May 2024, 16:00 (CEST)

Human medicines European public assessment report (EPAR): Ranexa (previously Latixa), ranolazine, Date of authorisation: 08/07/2008, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Ranexa (previously Latixa), ranolazine, Date of authorisation: 08/07/2008, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Date of authorisation: 23/10/2001, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Date of authorisation: 23/10/2001, Revision: 33, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness